Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis

NCT05133336 is registered in ClinicalTrials.gov with Zydus Therapeutics Inc. as lead sponsor.

NCT NCT05133336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05133336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis
Lead sponsor
Zydus Therapeutics Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
April 1, 2022
Completion date
May 7, 2025
Enrollment
196 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis